Insulin glargine/Lixisenatide

DRUG3 trials

Sponsors

Sanofi

Conditions

Type 2 Diabetes Mellitus

Phase 3

Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents

TerminatedNCT03434119

SanofiType 2 Diabetes Mellitus

Start: 2018-02-20End: 2019-01-07Updated: 2022-03-28

iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)

CompletedNCT05413369

SanofiType 2 Diabetes Mellitus

Start: 2022-07-07End: 2023-10-20Updated: 2025-09-24

Phase 4

Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus

CompletedNCT05114590

SanofiType 2 Diabetes Mellitus

Start: 2022-01-27End: 2023-04-14Updated: 2025-09-09

Related Papers

23-PUB: Efficacy and Safety of IGlarLixi vs. IDegAsp by Baseline HbA1c in Chinese People with T2D—Post Hoc Analyses of the SoliD Study

Diabetes2025-06-131 citations

24-PUB: The Efficacy and Safety of iGlarLixi in Insulin-Naïve Adults with Type 2 Diabetes (T2D) by Baseline Age, Sodium–Glucose Cotransporter 2 Inhibitor (SGLT2i) Use, and BMI—Post Hoc Analysis of Soli-CGM

Diabetes2025-06-13

1988-LB: Impact of Time of Injection Comparing iGlarLixi vs. IDegAsp in Chinese People with Type 2 Diabetes—Exploratory Analysis of the SoliD Study

Diabetes2025-06-13

Effect of <scp>iGlarLixi</scp> on continuous glucose monitoring—measured time in range in insulin‐naive adults with suboptimally controlled type 2 diabetes

Diabetes Obesity and Metabolism2025-02-042 citations

374-P: Impact of Sulfonylurea (SU) Use on Hypoglycemia and Continuous Glucose Monitoring (CGM) Metrics after 16 Weeks of iGlarLixi in Insulin-Naïve Adults with Type 2 Diabetes (T2D) and Mean A1C &gt;10%

Diabetes2024-06-14

1869-LB: Efficacy and Safety of iGlarLixi vs. IDegAsp in Chinese People with Type 2 Diabetes (T2D) Suboptimally Controlled with Oral Antidiabetic Drug(s) (OAD)—The SoliD Randomized Controlled Trial

Diabetes2024-06-14

839-P: Treatment Satisfaction and Time in Range (TIR) after 16 Weeks of iGlarLixi in Insulin-Naive Adults with Suboptimally Controlled Type 2 Diabetes

Diabetes2024-06-14